The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care."I woke up bent over with lower back pain every morning, which led to sciatica pain for 2 years. Turning over in bed feeling like a 50lb weight was attached to my lower back started around am and felt like a tight ball every morning that needed some air released. After trying 3 different medications, I started Cymbalta. Within two days and I was pain free in the morning and my sciatica pain eventually disappeared as well. At one point, I couldn't sit or stand for more than 15-30 minutes without getting up hunchbacked or feeling like my back was giving out. I’ve noticed that I yawned several times today and felt super uneased. I’m trying to flush my body with water to get rid of it. My quality of life had been taken over by what was becoming a 24/7 literal pain in my back. Terrible side effects.""I have been a nurse for the past 30 years, and my job requires me to be on my feet for 90% of the time I am at work. In late 2010, the FDA announced that it had approved duloxetine for the treatment of musculoskeletal pain, including chronic lower back pain ( The approval was based on data from “four double-blind, placebo-controlled, randomized clinical trials” in which investigators assessed the efficacy of Cymbalta in chronic low back pain and osteoarthritis. The FDA statement announcing approval of Cymbalta for this indication noted that “at the end of the study period, patients taking Cymbalta had a significantly greater pain reduction compared with placebo.” Although a recent overview of the available data noted that several trials have been of “short duration (12-13 weeks) and had high dropout rates” ( I), results on the efficacy of duloxetine in this patient population have generally been favorable. Placebo in Patients with Chronic Low Back Pain: A 12- Week, Fixed-dose, Randomized, Double-blind Trial” ( Sf V), researchers treated more than 400 adults with non-neuropathic chronic low back pain with duloxetine or placebo for 12 weeks. Participants all reported a pain intensity of 4 or greater on the Brief Pain Inventory (BPI) at baseline. After 12 weeks of treatment, patients who had received duloxetine reported a significantly greater reduction in average pain intensity scores (measured by BPI) compared to patients who received placebo. The duloxetine group also reported significantly greater improvements in Patient’s Global Impressions of Improvement measures, pain severity and interference (as measured by BPI), and 50% response rates (average BPI pain reduction of 50% or more at endpoint). Patients in the duloxetine group also reported better scores on the Roland Morris Disability Questionnaire and had improved 30% response rates.
The findings, which were presented at the American Academy of Pain Medicine's Annual Meeting in February 2010, were based on results from the Brief Pain Inventory (BPI). The BPI is a scientific tool used to rate a patient's degree of pain. In this experiment, researchers studied 401 patients with chronic low back pain. Over the course of 3 months, one group of patients received a 60-mg dose of Cymbalta, while the other group received a placebo. The patients in the Cymbalta group reported a significant reduction in their pain, compared to the placebo group. However, the researchers also noted that Cymbalta's negative side effects caused 30 of the 198 patients in the Cymbalta group to drop out of the study. These common side effects include nausea, headache, and dizziness. Among patients with chronic low back pain (CLBP), approximately 37% show signs of a neuropathic pain component (radicular pain). Therefore, the current study aimed to investigate the efficacy of duloxetine in the treatment of CLBP patients with neuropathic leg pain. The study was conducted as a prospective, randomized, placebo-controlled, double-blind crossover trial. CLBP with a visual analog scale (VAS) score greater than 5 and a neuropathic component that was assessed clinically and by the pain DETECT questionnaire (score 12) were required for inclusion. Patients were randomly assigned to either duloxetine or placebo for 4 weeks followed by a 2-week washout period before they crossed over to the alternate phase that lasted another 4 weeks. The primary outcome parameter was mean VAS score during the last week of treatment in each phase (VASIn this randomized, placebo-controlled crossover trial, patients with radicular symptoms experienced an average 32% reduction in pain after 4 weeks of treatment with duloxetine. The overall adverse event rate was similar between placebo and duloxetine treatments. It is also referred to as projected pain, which is caused by damage or irritation of peripheral nerves or nerve roots. However, radicular pain may also be triggered by local inflammatory processes that are caused by disc degeneration, even without verifiable mechanical compression. In a large, placebo-controlled 13-week trial, duloxetine led to a statistically significant pain reduction between weeks 3 and 11. Importantly, in all the aforementioned randomized controlled trials, CLBP patients with a neuropathic pain component were explicitly excluded.
This content has not been reviewed within the past year and may not represent Web MD's most up-to-date information. To find the most current information, please enter your topic of interest into our search box. 5, 2010 -- A drug used to treat depression, fibromyalgia, and diabetic nerve pain may also provide relief from hard-to-treat chronic low back pain. A new study shows people with chronic low back pain treated with Cymbalta experienced a significantly greater improvement in average pain scores than those treated with a placebo. Those treated with Cymbalta also reported a greater reduction in their perception of their low back pain and its interference in their daily lives. Chronic low back pain is defined as any pain in the low back that lasts more than 12 weeks. Researchers say the problem is difficult to treat because the cause is often unclear. "Chronic low back pain affects a significant number of people. A small number of children, teenagers, and young adults (up to 24 years of age) who took antidepressants (''mood elevators'') such as duloxetine during clinical studies became suicidal (thinking about harming or killing oneself or planning or trying to do so). Children, teenagers, and young adults who take antidepressants to treat depression or other mental illnesses may be more likely to become suicidal than children, teenagers, and young adults who do not take antidepressants to treat these conditions. However, experts are not sure about how great this risk is and how much it should be considered in deciding whether a child or teenager should take an antidepressant. Children younger than 18 years of age should not normally take duloxetine, but in some cases, a doctor may decide that duloxetine is the best medication to treat a child's condition. You should know that your mental health may change in unexpected ways when you take duloxetine or other antidepressants even if you are an adult over 24 years of age. These changes may occur even if you do not have a mental illness and you are taking duloxetine to treat a different type of condition. You may become suicidal, especially at the beginning of your treatment and any time that your dose is increased or decreased.
Jul 24, 2017. Duloxetine has demonstrated efficacy in chronic low back pain CLBP. We examined the predictors of response to duloxetine for CLBP. Jun 19, 2012. The management of osteoarthritis and chronic low back pain may. Keywords pain, musculoskeletal, duloxetine, osteoarthritis, low back.